Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451Continued ...
Bullish sentiment for CRISPR Therapeutics makes sense given the potential catalysts ahead. The stock could soar if it ...
College of Agriculture, Biotechnology & Natural Resources honors achievement in academics, leadership and research at 2026 ...
Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow. Read why I rate KRYS ...
Partnership combines venture creation and biologics discovery to accelerate novel medicines through human clinical proof of conceptFirst-of-its-kind collaboration between a specialist biotech venture ...
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.
Discover how CellResearchCorp pivoted from a biotech winter to a $25 million revenue turnaround in four years by focusing on ...
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 ...
An expert from Northway Biotech and Lithuania’s Minister of Economy and Innovation talk about how the country is poised to be ...
Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...
It's not the news that AbbVie needed, given the challenging year it is having.
Growing revenue and broker optimism are boosting confidence. The post 3 reasons why this ASX biotech stock could double in value appeared first on The Motley Fool Australia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results